Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.
about
Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Gene Therapy in the Nervous System: Failures and Successes.Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.
P2860
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Extended disease-free interval ...... G207 oncolytic viral therapy.
@en
Extended disease-free interval ...... G207 oncolytic viral therapy.
@nl
type
label
Extended disease-free interval ...... G207 oncolytic viral therapy.
@en
Extended disease-free interval ...... G207 oncolytic viral therapy.
@nl
prefLabel
Extended disease-free interval ...... G207 oncolytic viral therapy.
@en
Extended disease-free interval ...... G207 oncolytic viral therapy.
@nl
P2093
P2860
P356
P1476
Extended disease-free interval ...... G207 oncolytic viral therapy.
@en
P2093
James M Markert
James R Hackney
Kiran F Rajneesh
Thomas R Whisenhunt
P2860
P356
10.2147/OV.S62461
P577
2015-01-30T00:00:00Z